IMARC Group, a leading market research company, has recently releases report titled, “Metabolomics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028” The study provides a detailed analysis of the industry, including the global metabolomics market size, share, trends, and growth forecasts. The report also includes competitor and regional analysis and highlights the latest advancements in the market. Report Highlights
How big is the metabolomics market?
Report Attributes | Details |
Market Size in 2022 | US$ 2.4 Billion |
Market Forecast in 2028 | US$ 4.7 Billion |
Growth rate (2023 to 2028) | CAGR of 11.55% |
Base Year of the Analysis | 2022 |
Forecast Period | 2023-2028 |
What is metabolomics?
Metabolomics is the study and analysis of small molecules present in cells, biofluids, tissues, and organisms. It includes various steps, such as the acquisition, separation, detection of analytes, and data mining and extraction, and analysis. It involves various analytic techniques, such as nuclear magnetic resonance (NMR) spectroscopy and high-resolution mass spectrometry (HRMS). It serves as an effective tool in the diagnosis of a disease and facilitates the prediction of treatment response and survival. As it is also employed to detect the recurrence of a disease after therapy, metabolomics is gaining traction in biomarker and drug discovery, toxicology, nutrigenomics, and personalized medicines across the globe. Request Free Sample Report (Exclusive Offer on this report): https://www.imarcgroup.com/metabolomics-market/requestsampleWhat are the growth prospects and trends in the metabolomics industry?
At present, the growing global geriatric population and increasing prevalence of cancer and various cardiovascular and neurological disorders represent one of the key factors positively influencing the market. In addition, rising cases of inborn errors of metabolism (IEM), such as fructose intolerance, maple syrup urine disease (MSUD), fatty acid oxidation defects, mitochondrial disorders, and phenylketonuria (PKU) are catalyzing the demand for untargeted metabolomics for IEM screening worldwide. In line with this, increasing investments in research and development (R&D) activities and rising integration of machine learning (ML) algorithms with metabolomics to identify weight gain biomarkers is fueling the growth of the market.What is included in market segmentation?
The report has segmented the market into the following categories: Insights on Market Segmentation: Market Breakup by Product:- Metabolomics Instruments
- Metabolomics Bioinformatics Tools and Services
- Cancer
- Cardiovascular Disorders
- Neurological Disorders
- Inborn Errors of Metabolism
- Others
- Biomarker and Drug Discovery
- Toxicology
- Nutrigenomics
- Personalized Medicine
- Others
- North America
- Asia Pacific
- Europe
- United Kingdom
- Latin America
- Middle East and Africa
Who are the key players operating in the industry?
The report covers the major market players including:- Agilent Technologies, Inc. (A)
- Biocrates Life Sciences AG
- Bio-Rad Laboratories, Inc. (BIO)
- Bruker Corporation (BRKR)
- Danaher Corporation (DHR)
- HUMAN METABOLOME TECHNOLOGIES I (6090.T)
- Metabolon Inc.
- SHIMADZU CORP (SHMZF)
- Thermo Fisher Scientific Inc.
- Waters Corporation, etc.